Stephen Rohl is an associate who practises in intellectual property law, focusing on patent litigation. Stephen has represented a range of clients from the pharmaceutical, biotechnology and medical devices industries in infringement and revocation litigation in the Federal Court and the High Court of Australia, as well as in disputes in the Australian Patent Office. His experience includes matters involving patents relating to small molecules, antibodies and CRISPR gene editing technology, as well as the first occasion on which the High Court was called to rule on the patentability of methods of treatment of human beings and isolated nucleic acids. In addition to his law degree, Stephen holds a bachelor of science degree (honours) in applied chemistry.